|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600115975 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-04 14:25:01 |
|
注册时间: Date of Registration: |
2026-01-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
盐酸右美托咪定鼻喷雾剂用于骨科下肢手术椎管内麻醉穿刺产生镇静和遗忘作用的合适剂量 |
|
Public title: |
The appropriate dosage of Dexmedetomidine Hydrochloride Nasal Spray for sedation and amnesia during the puncture of intrathecal anesthesia in orthopedic lower limb surgery |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
盐酸右美托咪定鼻喷雾剂用于骨科下肢手术椎管内麻醉穿刺产生镇静和遗忘作用的合适剂量 |
|
Scientific title: |
The appropriate dosage of Dexmedetomidine Hydrochloride Nasal Spray for sedation and amnesia during the puncture of intrathecal anesthesia in orthopedic lower limb surgery |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈健祥 |
研究负责人: |
陈健祥 |
|
Applicant: |
Chen Jianxiang |
Study leader: |
Chen Jianxiang |
|
申请注册联系人电话: Applicant telephone: |
+86 173 5291 5264 |
研究负责人电话:
Study leader's |
+86 173 5291 5264 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
mzcjx1999@163.com |
研究负责人电子邮件: Study leader's E-mail: |
mzcjx1999@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国安徽省六安市金安区人民路76号 |
研究负责人通讯地址: |
中国安徽省六安市金安区人民路76号 |
|
Applicant address: |
No. 76, Renmin Road, Jin'an District, Lu'an City, Anhui Province, China |
Study leader's address: |
No. 76, Renmin Road, Jin'an District, Lu'an City, Anhui Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
六安市中医院 |
||
|
Applicant's institution: |
Lu'an City Traditional Chinese Medicine Hospital |
||
|
研究负责人所在单位: |
六安市中医院 |
||
|
Affiliation of the Leader: |
Lu'an City Traditional Chinese Medicine Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LASZYYLL-KY-2025048 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
六安市中医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Lu'an City Traditional Chinese Medicine Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-05 00:00:00 | ||
|
伦理委员会联系人: |
张士娟 |
||
|
Contact Name of the ethic committee: |
Zhang Shijuan |
||
|
伦理委员会联系地址: |
中国安徽省六安市金安区人民路76号 |
||
|
Contact Address of the ethic committee: |
No. 76, Renmin Road, Jin'an District, Lu'an City, Anhui Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 564 331 3309 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
六安市中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Lu'an City Traditional Chinese Medicine Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国安徽省六安市金安区人民路76号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 76, Renmin Road, Jin'an District, Lu'an City, Anhui Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Independent Research Project (Self-Funded) |
||||||||||||||||||||||
|
研究疾病: |
骨科下肢手术 |
||||||||||||||||||||||
|
Target disease: |
Orthopedic lower limb surgery |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过给予不同剂量的盐酸右美托咪定鼻喷雾剂,观察其对椎管内麻醉穿刺操作的镇静、遗忘程度,为临床上安全有效地使用盐酸右美托咪定鼻喷雾剂提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
By administering different doses of dexmedetomidine hydrochloride nasal spray, the study observes its effects on sedation and amnesia during spinal anesthesia puncture procedures, providing a basis for the safe and effective clinical use of dexmedetomidine hydrochloride nasal spray. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1) 签署知情同意书; (2) 本院择期行骨科下肢手术的患者; (3) 年龄18-65岁; (4) ASA分级(美国麻醉医师协会身体状况分级)为 I 或 II 级。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Sign the informed consent form; 2. Patients scheduled for elective orthopedic lower limb surgery at this hospital; 3. Aged 18-65 years; 4. ASA classification (American Society of Anesthesiologists physical status) of I or II. |
||||||||||||||||||||||
|
排除标准: |
(1) 长期或近期服用抗精神病、镇静或镇痛药物的病史; (2) 严重心、肺、肝、肾功能不全(ASA III级或以上); (3) 腰椎疾患和腰痛病史; (4) 凝血功能异常; (5) 正在参与另一项临床试验。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. History of long-term or recent use of antipsychotic, sedative, or analgesic drugs; 2. Severe heart, lung, liver, or kidney dysfunction (ASA grade III or above); 3. History of lumbar spine disorders and low back pain; 4. Abnormal coagulation function; 5. Currently participating in another clinical trial. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2026-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-05 00:00:00 至 To 2026-08-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
纳入研究的患者按1:1:1的比例被分配到25ug盐酸右美托咪定鼻喷雾剂(D1)组,50ug盐酸右美托咪定鼻喷雾剂(D2)组,0.9%氯化钠溶液(NS)组中。计算机生成的随机化方案由一名非盲法统计学家制定,分配方案装在按顺序编号的密封不透明信封中,不对研究人员公开。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients included in the study were randomly assigned in a 1:1:1 ratio to the 25 μg dexmedetomidine hydrochloride nasal spray (D1) group, the 50 μg dexmedetomidine hydrochloride nasal spray (D2) group, or the 0.9% sodium chloride solution (NS) group. The computer-generated randomization scheme was developed by an unblinded statistician, and the allocation was placed in sequentially numbered, sealed opaque envelopes, which were not disclosed to the researchers. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
对患者在资格评估和正式试验登记后立即打开随机化信封。由于患者需要遵守方案,因此不对其进行盲法操作。但是,外科医生、麻醉师、统计人员以及负责评估神经认知功能和术后临床结果的研究小组成员对患者的分配和治疗并不知情 |
|
Blinding: |
For patients, the randomization envelopes are opened immediately after eligibility assessment and formal trial registration. Since patients need to adhere to the protocol, they are not blinded. However, surgeons, anesthesiologists, statisticians, and research team members responsible for assessing neurocognitive function and postoperative clinical outcomes are unaware of the patients' allocation and treatment. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
实验结束后上传;国家生物信息中心 (https://ngdc.cncb.ac.cn/gsub/) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Upload after the experiment; National Center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
收 141 例患者的基础信息、AS评分、 血液动力学信息、术后睡眠质量、VAS评分、是否发生呕吐等,由专人用 CRF、电子病例等记录,设盲法和人员培训控质。数据管理:Excel 双人录入,SPSS 分析,双人核对,定期审查。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Collected basic information, AS scores, hemodynamic data, postoperative sleep quality, VAS scores, and occurrence of vomiting in 141 patients, which were recorded by dedicated personnel using CRF and electronic medical records, with blinding and staff training to control quality. Data management: dual entry in Excel, analysis with SPSS, double verification, and regular review. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |